TABLE 8.
Metabolites identified in pooled urine following oral single-dose (25 mg) and repeat-dose (15 mg/day for 14 days) administration of GSK3036656a
| Metabolite | Proposed structure | % oDRM, single dose (25 mg), day 1, 0–72 h (% dose) | % oDRM, repeat dose (15 mg), day 1, 0–24 h (% dose) | % oDRM, repeat dose (15 mg), day 14, 0–24 h (% dose) |
|---|---|---|---|---|
| P (GSK3036656) |  |
88 (44) | 92 (27) | 91 (71) |
| M1 (GSK3635633), oxidation and deboronation |  |
12 (6) | 8 (2) | 9 (7) |
| Total % dose | 50 | 30 | 78 | |
a
oDRM, observed drug-related material.